share_log

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Benzinga ·  Nov 18 23:11

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

  • Needham analyst Ami Fadia downgraded the rating for Biogen Inc. (NASDAQ:BIIB) from Buy to Hold and maintained the price target of $270. Biogen shares closed at $159.99 on Friday. See how other analysts view this stock.
  • Wolfe Research analyst Jacob Lacks downgraded the rating for Matson, Inc. (NYSE:MATX) from Outperform to Peer Perform. Matson shares closed at $160.65 on Friday. See how other analysts view this stock.
  • Barclays analyst Nicholas Campanella downgraded Pinnacle West Capital Corporation (NYSE:PNW) from Overweight to Equal-Weight and lowered the price target from $93 to $91. Pinnacle West Capital shares closed at $91.88 on Friday. See how other analysts view this stock.
  • Argus Research analyst John Eade downgraded the rating for Fortive Corporation (NYSE:FTV) from Buy to Hold. Fortive shares closed at $74.82 on Friday. See how other analysts view this stock.
  • Stifel analyst Nathan Jones downgraded Curtiss-Wright Corporation (NYSE:CW) from Buy to Hold and maintained the price target of $370. Curtiss-Wright shares closed at $358.35 on Friday. See how other analysts view this stock.

Considering buying BIIB stock? Here's what analysts think:

big

Read More:

  • How To Earn $500 A Month From Apple Stock
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment